Amylyx Pharmaceuticals (AMLX) News Today

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director George M. Milne, Jr. acquired 100,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were bought at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now owns 858,571 shares in the company, valued at $1,888,856.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,970,000 shares, an increase of 5.9% from the July 31st total of 1,860,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.3% of the company's stock are short sold.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 1,860,000 shares, a decline of 50.8% from the July 15th total of 3,780,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the short-interest ratio is currently 1.1 days. Approximately 4.1% of the shares of the company are short sold.

Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 3,780,000 shares, a decrease of 17.3% from the June 30th total of 4,570,000 shares. Currently, 8.2% of the shares of the stock are sold short. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 2.0 days.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight research firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and two have assigned a buy r

The Goldman Sachs Group increased their price target on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a "neutral" rating in a research report on Friday.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 4,570,000 shares, a drop of 36.6% from the June 15th total of 7,210,000 shares. Currently, 9.9% of the company's stock are sold short. Based on an average daily trading volume, of 1,990,000 shares, the short-interest ratio is currently 2.3 days.

HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has received an average rating of "Hold" from the eight analysts that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 7,570,000 shares, a decrease of 5.3% from the May 15th total of 7,990,000 shares. Approximately 16.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,370,000 shares, the short-interest ratio is currently 3.2 days.

Perceptive Advisors LLC lessened its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 30.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,869,125 shares of the company's stock after selling 819,

Avidity Partners Management LP lessened its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 96.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 64,501 shares of the company's stock after selling 1,692,43

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given an average recommendation of "Hold" by the eight research firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating on

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 7,990,000 shares, a drop of 6.1% from the April 30th total of 8,510,000 shares. Based on an average daily trading volume, of 3,350,000 shares, the short-interest ratio is presently 2.4 days. Approximately 17.4% of the shares of the company are short sold.

Franklin Resources Inc. raised its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 114.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,325,001 shares of the company's stock after acquiring an additional 707,

Mizuho reduced their price target on shares of Amylyx Pharmaceuticals from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. The firm had revenue of $88.64 million during the quarter, compared to analyst estimates of $113.26 million. During the same period in the previous year, the company earned $0.02 earnings per share.

HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a report on Friday.

Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.

Robert W. Baird reduced their price target on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday.